Karikó & Weissman: The mRNA Discovery, Its Vaccines, and the Honest Record

Kariko Weissman — scientific infographic poster

How this page works: it follows the same rules as our ivermectin-and-COVID record — every claim documented, every piece of evidence labeled by how strong it actually is, harms stated beside benefits, the strongest version of each side's argument given before it is weighed. Some of our readers received these vaccines and are glad; some refused and are glad; some believe they were harmed. This page is written to be honest with all three. Documenting a claim is not an endorsement of it — in either direction.

Table of Contents

  1. The Prize and the Two Scientists
  2. Why mRNA Was Considered a Dead End
  3. The 2005 Discovery: Pseudouridine
  4. From Lab Curiosity to Platform
  5. The 2020 Trials — What Held, What Didn't
  6. The Safety Record, Honestly
  7. The Mandates Are Not the Molecule
  8. Where the Critics Were Right — and Wrong
  9. Beyond COVID: The Real Pipeline
  10. What Karikó's Story Teaches
  11. Where Mainstream Medicine Agrees / What Remains Genuinely Debated
  12. Key Research Papers
  13. Connections
  14. Featured Videos

1. The Prize and the Two Scientists

On October 2, 2023, the Nobel Assembly at the Karolinska Institute awarded the Nobel Prize in Physiology or Medicine jointly to Katalin Karikó and Drew Weissman — in the committee's exact words, "for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19." Note what that citation actually rewards: not a vaccine, but a chemical discovery made in 2005, fifteen years before anyone had heard of SARS-CoV-2. That distinction matters throughout this page.

Katalin Karikó was born in 1955 in Szolnok, Hungary, and grew up in the small town of Kisújszállás in a one-room adobe house without running water. Her father was a butcher; she has said watching him work was her first biology lesson. She earned her PhD at the University of Szeged and worked at Hungary's Biological Research Centre until 1985, when the lab lost its funding and let her go. She, her husband Béla Francia, and their two-year-old daughter Susan left for America that year; Hungary's communist government restricted how much currency citizens could take abroad, so the family sold their car on the black market and sewed the proceeds — about $1,200 — inside Susan's teddy bear. It was everything they had.

At the University of Pennsylvania, where she landed in 1989, her conviction that messenger RNA could be turned into medicine met decades of rejection. Grant after grant was turned down. In 1995, Penn demoted her from the faculty track for failing to bring in funding — a demotion that arrived, as she later told the New York Times, in the same stretch of weeks as a cancer scare and with her husband stranded in Hungary by a visa problem. Most scientists would have changed fields or employers. She stayed, at a salary she has said never reached $60,000, and kept working on mRNA. (Persistence runs in the family: her daughter Susan Francia rowed in the American women's eight that won Olympic gold in 2008 and 2012.)

Drew Weissman, born in 1959 in Lexington, Massachusetts, is in most ways Karikó's temperamental opposite — a quiet, methodical physician-immunologist who avoids the spotlight. Diagnosed with type 1 diabetes at age five, he grew up understanding what it means to depend on a biomedical discovery every day of your life. He trained at Brandeis and Boston University, then spent his fellowship years at the NIH studying HIV in Anthony Fauci's laboratory before joining Penn in 1997 to hunt for an HIV vaccine.

The two met at a departmental photocopier shortly after Weissman arrived — in the late 1990s scientists still photocopied journal articles, and the two kept competing for the machine. Karikó made an offer: she could synthesize any mRNA he wanted. Weissman wanted an HIV vaccine. Neither got what they were looking for; what they got instead was the discovery that made mRNA medicine possible. By the time the Nobel came, Karikó had received the Lasker Award (2021) and the Breakthrough Prize (2022), and became the thirteenth woman ever to win the Medicine Nobel — twenty-eight years after the university sharing her stage had demoted her.

2. Why mRNA Was Considered a Dead End

The idea behind mRNA medicine is seductively simple. Messenger RNA is the cell's working copy of a gene — the instruction slip carried from the DNA archive to the protein factories. Inject a synthetic instruction slip, and the patient's own cells manufacture the therapeutic protein: no protein bioreactors, no viruses grown in eggs. In 1989, Robert Malone and colleagues showed mRNA packaged in fatty droplets could enter cells and be translated; in 1990, Jon Wolff's team showed even naked mRNA injected into mouse muscle produced protein. The concept worked.

The practice did not. Three problems buried the field for a generation:

  1. Synthetic mRNA triggered violent inflammation. The innate immune system — the body's ancient, hair-trigger first line of defense — treated lab-made mRNA as an invading virus. Animals given it developed inflammatory reactions; in some experiments mice became visibly sick. For a drug meant to be given to healthy people, this looked disqualifying.
  2. It made almost no protein. The same immune alarm that caused inflammation also shut down the cell's translation machinery, so the injected instructions were barely read before being destroyed. Tiny yield, big side effects — the worst possible ratio.
  3. Delivery was unsolved. mRNA is one of the most fragile molecules in biology; enzymes in blood shred it in minutes, and it cannot cross cell membranes on its own.

By the mid-1990s the field's verdict was in: DNA vaccines were the future; mRNA was a curiosity — too inflammatory, too unstable, too weak. Funding agencies agreed, which is why Karikó's grants kept failing and why her demotion looked, to her institution, like rational management. Note that the consensus was not stupid — synthetic mRNA genuinely was inflammatory and genuinely did underperform. It was wrong only in treating an unsolved problem as an unsolvable one. Her stubbornness was not a refusal to see the data; it was a refusal to accept that the data was the end of the story.

3. The 2005 Discovery: Pseudouridine

The breakthrough came from asking the question the field had stopped asking: why does the immune system attack synthetic mRNA when every cell in the body is full of its own mRNA and tolerates it completely? What is the difference between the mRNA a cell makes and the mRNA a machine makes?

Karikó and Weissman found the answer in a control experiment. When they exposed immune sentinel cells (dendritic cells) to different RNAs, transfer RNA — the small adapter that ferries amino acids — provoked almost no reaction, while their synthetic mRNA set off every alarm. The telling detail: tRNA is the most heavily chemically modified RNA in the cell. Natural RNA is not made of the four plain textbook bases; cells decorate it after synthesis with dozens of small alterations. One of the most common is pseudouridine (Ψ) — the same uridine base, rotated to connect to the sugar backbone through a carbon instead of a nitrogen. A tiny change, invisible to the protein-making machinery, visible to the immune system.

Their 2005 paper in Immunity showed that the innate immune system's pattern-recognition sensors — the Toll-like receptors (TLR3, TLR7, TLR8) that evolved to detect microbial RNA — are triggered by unmodified RNA and stand down when the RNA carries natural modifications like pseudouridine. Swap plain uridine for pseudouridine in synthetic mRNA and the molecule stops looking like a virus. The alarm goes quiet. And — as they showed in a follow-up paper in Molecular Therapy in 2008 — with the alarm quiet, the cell's translation machinery is no longer suppressed, so the modified mRNA produces far more protein while causing far less inflammation. Both halves of the field's death sentence on mRNA were reversed by the same single atom-level substitution.

The reception was a lesson in how science actually works. Karikó has recounted that Nature rejected the manuscript within 24 hours as incremental. After further rejections it appeared in Immunity — and was then largely ignored for years, cited only a handful of times. Two groups read it and understood. Stem-cell biologist Derrick Rossi used modified mRNA to reprogram cells in 2010 and co-founded a company named for the idea — Moderna, from "modified RNA." And Germany's cancer-vaccine company BioNTech licensed the work and in 2013 hired Karikó herself, after Penn declined to reinstate her and, in her telling, pushed her out of her lab space; colleagues mocked her move to a company that, she noted, did not even have a website. The COVID-19 vaccines from both companies carry a slight variant of the discovery — N1-methylpseudouridine — in every dose. This 2005 chemistry, not the 2020 emergency, is what the Nobel rewarded.

4. From Lab Curiosity to Platform

Modified mRNA solved the immunity problem but not delivery: the molecule still could not survive the bloodstream or enter cells on its own. That solution came from a different research lineage — lipid nanoparticles (LNPs), microscopic fat droplets of four components (an ionizable lipid that turns positively charged only in acidic environments, a PEG-lipid, cholesterol, and a structural phospholipid), grown out of decades of work by Pieter Cullis's Vancouver group and others on delivering gene-silencing RNA; the first LNP drug, patisiran, was approved in 2018. Wrap modified mRNA in an LNP and you have the full platform: an instruction slip the immune system tolerates, inside an envelope that delivers it into cells. Karikó and Weissman published the nucleoside-modified mRNA-LNP vaccine approach in the mid-2010s, and BioNTech and Moderna built their pipelines on that foundation.

Then came the demonstration of what a platform technology means. On January 10–11, 2020, Chinese and Australian scientists posted the genetic sequence of the new Wuhan coronavirus on the open internet. Because an mRNA vaccine is software — the "hardware" of modified mRNA plus LNP stays the same and only the encoded protein changes — Moderna finalized its vaccine design within about two days of the sequence appearing, before a single case had been confirmed in the United States. Sixty-six days later, on March 16, 2020, the first trial volunteer was dosed. BioNTech ran its own "Project Lightspeed" and partnered with Pfizer for trials and manufacturing. No previous vaccine technology had ever moved at a fraction of that speed.

Honesty requires stating that the vaccines were a stack of discoveries, not one: the base modification (Karikó and Weissman), the LNP delivery system (Cullis and many others), and the "2P" trick of locking the coronavirus spike protein in its prefusion shape — worked out for other coronaviruses years earlier by Barney Graham, Jason McLellan, Kizzmekia Corbett and colleagues — without which the vaccines would have shown the immune system a floppy, wrong-shaped target. Nobel prizes flatten teams into names; the record should not.

5. The 2020 Trials — What Held, What Didn't

The pivotal randomized trials were, by any standard, large, and their initial results striking. The Pfizer-BioNTech trial (Polack et al., NEJM) randomized 43,548 people: 8 symptomatic COVID cases in the vaccine arm versus 162 on placebo — 95.0% efficacy, with 9 of 10 severe cases in the placebo group. The Moderna trial (Baden et al., NEJM) randomized 30,420: 11 cases versus 185 — 94.1% efficacy, with all 30 severe cases on placebo. These are the numbers "95% effective" came from, and as randomized, placebo-controlled evidence against the strains circulating in 2020, they were real.

What happened afterward needs to be stated just as plainly, in both directions:

A fair summary of the efficacy record: the headline promise of stopping symptomatic infection proved temporary and variant-sensitive, while the protection that mattered most — against dying — proved substantial and durable, greatest in the oldest and sickest. Both the reader who feels misled by "95%" and the reader whose elderly parents came through the Delta wave vaccinated and alive are reading the same record.

6. The Safety Record, Honestly

These vaccines were given to billions of people, so the safety record is enormous in both senses: enormous reassurance on the catastrophic claims, and enough statistical power to detect real harms that 30,000–44,000-person trials could never see. Per site policy, each claim below is given in its strongest form, then labeled by what the evidence shows.

Documented harms — real, replicated, accepted by regulators

Claims large surveillance did not support

Still argued in good faith

7. The Mandates Are Not the Molecule

The Nobel Prize honored a piece of chemistry. Vaccine mandates — employment requirements, travel passes, school rules — were policy decisions made by governments and employers, and no molecule can be blamed or credited for them. This site's readers hold strong views here, and the two things this page most wants to keep separate are the science and the coercion.

The honest case against the mandates: their peak enforcement came in late 2021 and 2022, precisely as waning infection-blocking eroded the strongest rationale — "your vaccination protects others"; they largely refused to recognize recovered patients' natural immunity, which the same journals publishing the trials had documented as substantial; they applied uniform requirements to young healthy men, in whom the risk-benefit calculus was closest and the myocarditis signal concentrated; and people lost jobs over a dose that, within a year, several national regulators would stop even recommending for their age group. For many readers the mandates turned a medical option into a loyalty test, and the resulting resentment is rational, documented, and still depressing confidence — including in routine childhood vaccines that have nothing to do with mRNA.

The honest case for the institutions: those decisions were made in a mass-casualty emergency, by officials watching hospitals overflow, on the information available at the time — which in early-to-mid 2021 genuinely showed large reductions in infection and transmission against the then-circulating strains; mandates measurably raised uptake in the groups at highest risk of dying; and waiting for complete data is itself a decision with a body count when ICUs are full.

Where that leaves this page: a reader can hold the 2005 discovery as brilliant, the 2020 trials as real, the myocarditis signal as real, and the mandates as overreach — without contradiction. The molecule and the mandate must be judged separately. The failure to keep them separate — officials treating doubts about policy as doubts about chemistry, critics treating objections to coercion as proof the chemistry was fake — damaged trust in both directions.

8. Where the Critics Were Right — and Wrong

Mirroring our ivermectin scorecard, here is the ledger for both camps, stated without flinching in either direction.

What the institutions got right

What the institutions got wrong

What the critics got right

What the critics got wrong

The pattern, as on our ivermectin page, is symmetrical: each camp was most reliable exactly where it claimed the other could not be trusted, and least reliable where its own identity was at stake. The institutions were right about the molecule and wrong about their own certainty; the critics were right about several harms and wrong about the catastrophe.

9. Beyond COVID: The Real Pipeline

Whether mRNA medicine is a one-pandemic wonder or a durable platform is being decided now, in trials. The honest status report, with evidence tiers stated:

Two forces now pull on this pipeline from opposite directions: oncology results strong enough to attract enormous investment, and a political turn — including the 2025 cancellation of roughly half a billion dollars of US federal mRNA vaccine-development funding — celebrated by the platform's critics as accountability, condemned by its developers as retribution. The trials will outlast both readings.

10. What Karikó's Story Teaches

Strip away the pandemic and the politics, and what remains is one of the cleanest persistence stories in science. A scientist is told for decades, by every gatekeeping mechanism her profession has — grant committees, tenure committees, journal editors — that her idea is a dead end. She is demoted for it in 1995. She is, by her own account, pushed out of her lab and toward retirement in 2013. She joins a foreign startup without a website. And the idea she refused to abandon becomes the fastest-deployed vaccine technology in history, while the institution that demoted her earns hundreds of millions licensing her patents and then celebrates her Nobel as its own. Karikó has been notably unbitter about it, crediting the stress research of fellow Hungarian Hans Selye for her habit of focusing only on what she could control — the next experiment — not the verdicts of committees.

The uncomfortable lesson is about the credit-and-funding system rather than about her. Peer review and grant scoring are consensus machines: superb at filtering out most bad ideas, structurally blind to the rare unfashionable idea that is right, because reviewers are drawn from the consensus the idea contradicts. Nature's reported 24-hour rejection of the 2005 paper as "incremental" belongs in the same museum as the rejections that greeted Tu Youyou's artemisinin work and Barry Marshall's ulcer bacterium. The system also flattens credit: the Nobel names two people for a stack of discoveries that also required the LNP chemists and the spike-stabilization biologists (Section 4) — and one early contributor, Robert Malone, whose 1989 transfection experiments are part of the documented pre-history and who later became one of the vaccines' most prominent critics, publicly contends his role was erased. Readers will judge that dispute themselves; his early work and the Nobel committee's chosen citation — which honors the base-modification discovery specifically — are both part of this record.

And there is a symmetry worth naming on a site like this one: the same lesson — consensus can be wrong, and the record must stay open to the stubborn dissenter with data — is claimed today by critics of these very vaccines. The lesson is real, and Karikó's career teaches its second half too: she won not by insisting louder but by producing controlled experiments that survived every attempt to knock them down. That standard applies to everyone in this story — institutions and critics alike.

11. Where Mainstream Medicine Agrees / What Remains Genuinely Debated

Where mainstream medicine agrees

What remains genuinely debated

12. Key Research Papers

  1. Karikó K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 2005;23(2):165-75
  2. Karikó K, Muramatsu H, Welsh FA, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther 2008;16(11):1833-40
  3. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines — a new era in vaccinology. Nat Rev Drug Discov 2018;17(4):261-279
  4. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020;383(27):2603-2615
  5. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021;384(5):403-416
  6. Oster ME, Shay DK, Su JR, et al. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. JAMA 2022;327(4):331-340
  7. Patone M, Mei XW, Handunnetthi L, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med 2022;28(2):410-422
  8. Edelman A, Boniface ER, Benhar E, et al. Association Between Menstrual Cycle Length and Coronavirus Disease 2019 (COVID-19) Vaccination: A U.S. Cohort. Obstet Gynecol 2022;139(4):481-489
  9. Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. N Engl J Med 2021;385(24):e83
  10. Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet 2022;399(10328):924-944
  11. Weber JS, Carlino MS, Khattak A, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 2024;403(10427):632-644

Live PubMed Searches

  1. Nucleoside-modified mRNA vaccines
  2. mRNA vaccine myocarditis surveillance
  3. COVID vaccine effectiveness waning
  4. mRNA cancer vaccine trials
  5. Lipid nanoparticle mRNA delivery

Connections

Back to top